To bypass biological barriers and thus reduce the attrition rate of drugs and increase drug or diagnosis efficiency, VECT-HORUS invests its efforts in targeted delivery by conjugating therapeutics or imaging agents to “molecular vectors” that specifically target receptors involved in Receptor Mediated Transport (RMT, a physiological system for the transport into cells of endogenous substances). This targeting approach is presently considered as one of the most effective and safest way to by-pass cell barriers for delivering biomolecules to the brain, to target tumours and diseased tissues. The company has already established the proof of concept of its technology in animal models by vectorizing various molecules including small molecules, peptides and large molecules such as antibodies.